Lancet HIV

metrics 2024

Advancing the frontiers of HIV research.

Introduction

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

Metrics 2024

SCIMAGO Journal Rank4.42
Journal Impact Factor12.80
Journal Impact Factor (5 years)11.80
H-Index81
Journal IF Without Self12.80
Eigen Factor0.02
Normal Eigen Factor3.36
Influence5.46
Immediacy Index3.70
Cited Half Life3.80
Citing Half Life4.40
JCI2.42
Total Documents1490
WOS Total Citations5604
SCIMAGO Total Citations16678
SCIMAGO SELF Citations692
Scopus Journal Rank4.42
Cites / Document (2 Years)4.90
Cites / Document (3 Years)5.24
Cites / Document (4 Years)4.82

Metrics History

Rank 2024

Scopus

Infectious Diseases in Medicine
Rank #19/344
Percentile 94.48
Quartile Q1
Epidemiology in Medicine
Rank #9/148
Percentile 93.92
Quartile Q1
Immunology in Immunology and Microbiology
Rank #21/236
Percentile 91.10
Quartile Q1
Virology in Immunology and Microbiology
Rank #9/80
Percentile 88.75
Quartile Q1

IF (Web Of Science)

IMMUNOLOGY
Rank 8/181
Percentile 95.90
Quartile Q1
INFECTIOUS DISEASES
Rank 4/132
Percentile 97.30
Quartile Q1

JCI (Web Of Science)

IMMUNOLOGY
Rank 10/181
Percentile 94.48
Quartile Q1
INFECTIOUS DISEASES
Rank 8/132
Percentile 93.94
Quartile Q1

Quartile History

Similar Journals

AIDS EDUCATION AND PREVENTION

Fostering Insight to Combat HIV/AIDS Challenges
Publisher: GUILFORD PUBLICATIONS INCISSN: 0899-9546Frequency: 6 issues/year

AIDS Education and Prevention is a distinguished journal dedicated to the exploration of strategies for HIV/AIDS education, prevention, intervention, and policy. Published by Guilford Publications Inc, this journal has been a pivotal resource in the fields of Health (social science), Infectious Diseases, Medicine, and Public Health since its inception in 1989, and continues to be influential through 2024. With its respectable placement in the Q2 category across multiple disciplines, it offers high-impact research and practical insights that are essential for researchers, healthcare professionals, and students alike. Although not an Open Access journal, its compelling content and strict peer-review processes ensure that published works maintain high academic standards. The journal's contributions are integral in addressing the challenges surrounding HIV prevention and education, fostering a deeper understanding and knowledge that can lead to effective community responses.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Transforming Clinical Practice in Infectious Diseases
Publisher: ELSEVIERISSN: 2405-5794Frequency: 4 issues/year

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

Pioneering research to combat HIV in Southern Africa.
Publisher: AOSISISSN: 1608-9693Frequency: 1 issue/year

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, published by AOSIS, stands as a vital resource in the field of Infectious Diseases, particularly focusing on HIV medicine. With an ISSN of 1608-9693 and E-ISSN 2078-6751, this Open Access journal has been dedicated to disseminating cutting-edge research since 2001, ensuring that findings are accessible to a global audience of researchers, healthcare professionals, and students. Operating out of South Africa, the journal has earned a position in the Q3 quartile for Infectious Diseases, reflecting its commitment to advancing the understanding and treatment of HIV-related issues. Its Scopus ranking, presently at #207 out of 344, further emphasizes its scholarly influence, positioning it as an essential publication within the medical community. The journal aims to foster collaboration and innovation in HIV research and practice, bridging gaps between theory and real-world application to improve health outcomes in southern Africa and beyond.

INTERVIROLOGY

Uncovering breakthroughs in virology and infectious diseases.
Publisher: KARGERISSN: 0300-5526Frequency: 6 issues/year

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

JOURNAL OF INFECTIOUS DISEASES

Advancing the Frontiers of Infectious Disease Research
Publisher: OXFORD UNIV PRESS INCISSN: 0022-1899Frequency: 24 issues/year

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

AIDS RESEARCH AND HUMAN RETROVIRUSES

Driving Excellence in HIV and Retrovirus Studies
Publisher: MARY ANN LIEBERT, INCISSN: 0889-2229Frequency: 12 issues/year

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

Journal of Virus Eradication

Transforming knowledge into action against viruses.
Publisher: MEDISCRIPT LTDISSN: 2055-6640Frequency: 4 issues/year

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

AIDS

Elevating Science, Enhancing Practice
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0269-9370Frequency: 15 issues/year

AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.

CURRENT HIV RESEARCH

Unveiling the Latest in HIV Advancements
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-162XFrequency: 6 issues/year

Current HIV Research is a pivotal journal dedicated to the latest advancements in the field of HIV research, published by Bentham Science Publishers Ltd. With a commitment to disseminating high-quality research, this journal serves as a critical resource for researchers, healthcare professionals, and students interested in infectious diseases and virology. The journal has an ISSN of 1570-162X and an E-ISSN of 1873-4251, reflecting its commitment to contemporary digital scholarship. Given its publication history spanning from 2003 to 2024, the journal has continually provided insights and peer-reviewed articles that foster knowledge and innovation in HIV research. Although it currently holds a Q3 ranking in Infectious Diseases and a Q4 ranking in Virology, these rankings underscore its importance as an emerging platform for critical research dialogue. Despite not being an Open Access journal, 'Current HIV Research' ensures that cutting-edge studies reach relevant practitioners and contribute to ongoing discourse in the medical community. By fostering an informed approach to HIV and its implications, this journal is an invaluable asset to those committed to advancing their expertise in this crucial area of health science.

AIDS Research and Treatment

Empowering research, enhancing treatment.
Publisher: HINDAWI LTDISSN: 2090-1240Frequency: 1 issue/year

AIDS Research and Treatment is a premier open access journal published by HINDAWI LTD, dedicated to advancing the understanding and treatment of HIV/AIDS and related conditions. Launched in 2010, the journal has established itself as a vital resource for researchers, healthcare professionals, and students in the fields of Dermatology, Immunology, Infectious Diseases, and Public Health. With a notable 2023 impact factor reflected in its Q2 and Q3 quartile rankings across key medical categories, the journal plays a critical role in disseminating high-quality research and fostering innovation in the prevention and treatment of AIDS. It provides a wide range of open access options, enabling easier dissemination and increased visibility of research findings globally. As the landscape of HIV/AIDS research continues to evolve, AIDS Research and Treatment remains at the forefront, ensuring crucial insights and developments are shared to enhance public health outcomes.